Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. downgraded their outlook for Rallybio (NasdaqGS:RLYB) from Buy to ...

H.C. Wainwright downgraded Tempest Therapeutics (TPST) to Neutral from Buy without a price target after the company announced it is seeking to ...

H.C. Wainwright analyst Yi Chen initiated coverage of Bionano Genomics (BNGO) with a Buy rating and $10 price target Bionano is a ...

HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS – Free Report) in a report released on ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy recommendation. As of April 2, 2025, the average one-year price target ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Fintel reports that on April 8, 2025, HC Wainwright & Co. initiated coverage of VolitionRx (NYSEAM:VNRX) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

On Tuesday, H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Lexeo Therapeutics (NASDAQ:LXEO) with a steady price target of $23.00, representing significant upside from the current ...